Tc Biopharm (Holdings) PLC (TCBWF) — SEC Filings

Overview

Tc Biopharm (Holdings) PLC (TCBWF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Nov 17, 2025: TC BioPharm (Holdings) plc, a biopharmaceutical company, filed a Form 6-K on November 17, 2025. The filing is a report of a foreign private issuer and does not contain specific financial details or operational updates beyond its classification and filing status.

Sentiment Summary

Across 43 filings, the sentiment breakdown is: 2 bullish, 4 bearish, 37 neutral. The dominant filing sentiment for Tc Biopharm (Holdings) PLC is neutral.

Filing Type Overview

Tc Biopharm (Holdings) PLC (TCBWF) has filed 22 6-K, 1 20-F, 3 SC 13G/A, 12 8-K, 2 DEF 14A, 1 10-Q, 1 10-K/A, 1 10-K with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (43)

• TC BioPharm Files 6-K Report — 6-K · Nov 17, 2025 Risk: low
  TC BioPharm (Holdings) plc, a biopharmaceutical company, filed a Form 6-K on November 17, 2025. The filing is a report of a foreign private issuer and does not
• TC BioPharm Files 6-K Report — 6-K · Oct 7, 2025 Risk: low
  TC BioPharm (Holdings) plc filed a Form 6-K on October 7, 2025, reporting as a foreign private issuer. The company, incorporated in Scotland, operates in the bi
• TC BioPharm Files Form 6-K for September 2025 — 6-K · Sep 2, 2025 Risk: low
  TC BioPharm (Holdings) plc, a biopharmaceutical company, filed a Form 6-K on September 2, 2025. This report is for the month of September 2025 and indicates the
• TC BioPharm Files August 2025 6-K Report — 6-K · Aug 5, 2025 Risk: low
  TC BioPharm (Holdings) plc, a biopharmaceutical company, filed a Form 6-K on August 5, 2025. The filing is a report of a foreign private issuer for the month of
• TC BioPharm Files 6-K Report — 6-K · May 27, 2025 Risk: low
  TC BioPharm (Holdings) plc filed a Form 6-K on May 27, 2025, reporting as a foreign private issuer. The company, previously known as TC BioPharm (Holdings) Ltd
• TC BioPharm Files 2024 Annual Report — 20-F · May 9, 2025 Risk: medium
  TC BioPharm (Holdings) plc filed its annual report on Form 20-F for the fiscal year ending December 31, 2024. The company, primarily involved in biological prod
• TC BioPharm Files May 2025 6-K Report — 6-K · May 6, 2025 Risk: low
  TC BioPharm (Holdings) plc filed a Form 6-K on May 6, 2025, reporting its activities for the month of May 2025. The company, incorporated in Scotland, United Ki
• TC BioPharm to be Delisted from Nasdaq — 6-K · Mar 21, 2025 Risk: high
  TC BioPharm (Holdings) plc announced on March 21, 2025, that it received notice from the Nasdaq Hearings Panel to delist its securities from The Nasdaq Stock Ma
• TC BioPharm Changes ADS Ratio to 200:1 — 6-K · Feb 10, 2025 Risk: medium
  TC BioPharm (Holdings) PLC announced on February 5, 2025, a change in its American Depositary Shares (ADSs) to ordinary share ratio. The new ratio is one ADS re
• TC BioPharm Faces Nasdaq Delisting Risk Over Bid Price — 6-K · Jan 8, 2025 Risk: medium
  On January 3, 2025, TC BioPharm (Holdings) plc received a notification from Nasdaq indicating that its American Depositary Shares (ADS) have not met the minimum
• TC BioPharm Approves Special ADS Dividend — 6-K · Dec 31, 2024 Risk: low
  TC BioPharm (Holdings) plc announced on December 18, 2024, that its Board of Directors has approved a special dividend. Shareholders will receive 0.25 American
• TC BioPharm Shareholder Meeting Approves All Resolutions — 6-K · Dec 30, 2024 Risk: low
  On December 30, 2024, TC BioPharm (Holdings) plc held a general meeting of shareholders where all proposed resolutions were passed. The company, also known as T
• TC Biopharm Taps Wainwright for At-the-Market Offering — 6-K · Dec 17, 2024 Risk: medium
  On December 16, 2024, TC Biopharm (Holdings) PLC entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC. This agreement allows the com
• TC BioPharm Files 6-K Report — 6-K · Dec 16, 2024 Risk: low
  TC BioPharm (Holdings) plc, a biopharmaceutical company, filed a Form 6-K on December 16, 2024. The filing is a report of a foreign private issuer for the month
• TC BioPharm Files 6-K for June 2024 Period — 6-K · Nov 25, 2024 Risk: low
  TC BioPharm (Holdings) plc, incorporated in Scotland, filed a Form 6-K on November 25, 2024, reporting for the period ending June 30, 2024. The company, previou
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• TC Biopharm Awards Bonuses to CEO and CFO — 6-K · Oct 11, 2024 Risk: low
  On September 2, 2024, TC Biopharm (Holdings) PLC's board of directors approved a one-time bonus of $125,000 for both CEO Bryan Kobel and CFO Martin Thorp. This
• TC BioPharm Enters Securities Purchase Agreement — 6-K · Aug 30, 2024 Risk: medium
  On August 28, 2024, TC BioPharm (Holdings) plc entered into a Securities Purchase Agreement with accredited investors to issue and sell shares. The filing is a
• TC BioPharm Regains Nasdaq Listing Compliance — 6-K · Aug 23, 2024 Risk: medium
  On August 21, 2024, TC BioPharm (Holdings) plc received a notice from the Nasdaq Stock Market stating that the company has regained compliance with the minimum
• TC BioPharm Announces Public Offering Agreement — 6-K · Aug 15, 2024 Risk: medium
  On August 13, 2024, TC BioPharm (Holdings) plc entered into a Securities Purchase Agreement with an investor for a public offering. The filing does not specify
• TC BioPharm Changes ADS Ratio — 6-K · Aug 8, 2024 Risk: medium
  TC BioPharm (Holdings) PLC announced on July 31, 2024, a change in its American Depositary Shares (ADSs) to ordinary share ratio. The new ratio is one ADS repre
• TC BioPharm Files 6-K Report — 6-K · Aug 6, 2024 Risk: low
  TC BioPharm (Holdings) plc, a biotechnology company, filed a Form 6-K on August 6, 2024. The filing is a report of a foreign private issuer and does not contain
• TC BioPharm Files 6-K Report — 6-K · Jul 29, 2024 Risk: low
  TC BioPharm (Holdings) plc filed a Form 6-K on July 29, 2024, reporting as a foreign private issuer. The company, previously known as TC BioPharm (Holdings) Ltd
• TC BioPharm Files 6-K Report — 6-K · Jul 1, 2024 Risk: low
  TC BioPharm (Holdings) plc, a biotechnology company, filed a Form 6-K on July 1, 2024. The filing is a report of a foreign private issuer for the month of July
• TC BioPharm Board Changes Announced — 8-K · Jun 28, 2024 Risk: medium
  TC BioPharm (Holdings) plc announced on June 26, 2024, a change in its board of directors. Specifically, the company reported the departure of certain officers
• TC BioPharm Files Definitive Proxy Statement — DEF 14A · Jun 7, 2024 Risk: low
  TC BioPharm (Holdings) plc filed a definitive proxy statement (DEF 14A) on June 7, 2024. The filing pertains to the company's annual meeting and related corpora
• TC Biopharm Faces Delisting Concerns — 8-K · May 29, 2024 Risk: high
  TC Biopharm (Holdings) plc filed an 8-K on May 29, 2024, reporting a notice of delisting or failure to satisfy continued listing rules as of May 24, 2024. The c
• TC Biopharm Files 8-K for Other Events — 8-K · May 20, 2024 Risk: medium
  TC Biopharm (Holdings) plc filed an 8-K on May 20, 2024, reporting "Other Events." The filing does not contain specific financial figures or detailed event desc
• TC BioPharm (Holdings) plc Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 15, 2024 Risk: low
  TC BioPharm (Holdings) plc (TCBWF) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. TC BioPharm (Holdings) plc filed a 10-Q report for the period e
• TC BioPharm Files 8-K: Material Agreement & Equity Sales — 8-K · May 8, 2024 Risk: medium
  On May 6, 2024, TC BioPharm (Holdings) plc entered into a material definitive agreement. The company also reported on unregistered sales of equity securities an
• TC Biopharm Files 8-K for Financials — 8-K · May 6, 2024 Risk: low
  TC Biopharm (Holdings) plc filed an 8-K on May 6, 2024, reporting events as of May 1, 2024. The filing primarily concerns financial statements and exhibits, wit
• TC BioPharm Files Amended 10-K for Fiscal Year Ended December 31, 2023 — 10-K/A · Apr 29, 2024 Risk: low
  TC BioPharm (Holdings) plc (TCBWF) filed a Amended Annual Report (10-K/A) with the SEC on April 29, 2024. TC BioPharm (Holdings) plc filed an amended 10-K repor
• TC Biopharm Files 8-K, Reports Corporate Changes — 8-K · Apr 4, 2024 Risk: medium
  TC Biopharm (Holdings) plc filed an 8-K on April 4, 2024, reporting events as of April 1, 2024. The filing indicates changes in the company's structure and pote
• TC BioPharm (Holdings) plc Files 2023 Annual Report on Form 10-K — 10-K · Apr 1, 2024 Risk: medium
  TC BioPharm (Holdings) plc (TCBWF) filed a Annual Report (10-K) with the SEC on April 1, 2024. TC BioPharm (Holdings) plc filed its annual report on Form 10-K f
• TC Biopharm (Holdings) plc Files 8-K on Shareholder Vote — 8-K · Mar 19, 2024 Risk: medium
  TC Biopharm (Holdings) plc filed an 8-K on March 19, 2024, reporting that a matter was submitted to a vote of security holders on March 14, 2024. The filing doe
• TC Biopharm Raises $500K in Private Placement — 8-K · Mar 18, 2024 Risk: medium
  On March 12, 2024, TC Biopharm (Holdings) plc announced the closing of a private placement of 1,000,000 ordinary shares at a price of $0.50 per share, raising g
• TC Biopharm Reports Equity Sales & Director Changes — 8-K · Mar 12, 2024 Risk: medium
  TC Biopharm (Holdings) plc filed an 8-K on March 12, 2024, reporting on unregistered sales of equity securities and changes in directors and officers. The filin
• TC Biopharm Reports Director Changes and Officer Appointments — 8-K · Mar 6, 2024 Risk: medium
  TC Biopharm (Holdings) plc filed an 8-K on March 6, 2024, reporting events as of February 29, 2024. The filing primarily concerns the departure of directors or
• TC BioPharm (Holdings) plc Announces General Meeting Details — DEF 14A · Feb 20, 2024 Risk: low
  TC BioPharm (Holdings) plc (TCBWF) filed a Proxy Statement (DEF 14A) with the SEC on February 20, 2024. TC BioPharm (Holdings) plc will hold a General Meeting o
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• TC BioPharm Files 8-K on Feb 14 for Feb 13 Event — 8-K · Feb 14, 2024 Risk: medium
  TC BioPharm (Holdings) PLC filed an 8-K with the SEC on February 14, 2024, reporting an event that occurred on February 13, 2024. The filing indicates disclosur
• MEDINET Co. Amends TC BioPharm Stake Filing — SC 13G/A · Jan 29, 2024
  MEDINET Co., Ltd. filed an amended SC 13G/A on January 29, 2024, indicating their beneficial ownership in TC BioPharm (Holdings) plc as of December 31, 2023. Th
• TC BioPharm Faces Nasdaq Delisting Warning Over Bid Price Rule — 8-K · Jan 4, 2024
  TC BioPharm (Holdings) plc announced on January 4, 2024, that it received a delisting notice from Nasdaq on December 28, 2023, because its American Depositary S

Risk Profile

Risk Assessment: Of TCBWF's 39 recent filings, 2 were flagged as high-risk, 18 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Bryan Kobel
• Martin Thorp

Industry Context

TC BioPharm operates in the biotechnology sector, specifically focusing on biological products.

Top Tags

regulatory-filing (9) · sec-filing (7) · foreign-private-issuer (6) · biotech (6) · reporting (4) · TC BioPharm (4) · 6-k (3) · 6-K (3) · biopharmaceutical (2) · delisting (2)

Key Numbers

• SEC File Number: 001-41231 — Identifies the company's filing with the SEC
• Fiscal Year End: 20241231 — The period covered by the 20-F filing.
• Filing Date: 20250509 — The date the 20-F was submitted to the SEC.
• ADS to Ordinary Share Ratio: 200 — The new ratio means 1 ADS now represents 200 ordinary shares.
• Grace Period: 180 — Days provided by Nasdaq to regain compliance
• Minimum Bid Price: $1.00 — Requirement for Nasdaq listing
• ADS Dividend Ratio: 0.25 — Shareholders receive 0.25 ADSs for every 1 ADS held.
• Bonus per Executive: $125,000 — One-time bonus granted to CEO and CFO.
• Total Bonus Payout: $250,000 — Aggregate of bonuses for CEO and CFO.
• Previous ADS Ratio: 20:1 — Represents the old ratio of American Depositary Shares to ordinary shares.
• New ADS Ratio: 1:1 — Represents the new ratio of American Depositary Shares to ordinary shares, effective July 31, 2024.
• Reporting Period End Date: 2024-03-31 — Conformed period of report
• SIC Code: 2836 — Standard Industrial Classification
• Commission File Number: 001-41231 — SEC Commission File Number
• ZIP Code: ML1 4WR — ZIP code for principal executive offices

Related Companies

TCBP

Frequently Asked Questions